Ganga Pharmaceuticals (539680) H2 25/26 earnings summary

Executive summary

• Audited financial results for the half year and full year ended March 31, 2026, were approved by the Board on May 21, 2026.

• Statutory auditors issued an unmodified opinion on the financial statements.

Financial highlights

• Revenue from operations for FY26 was ₹282.79 lakhs, up from ₹263.74 lakhs year-over-year.

• Net profit for FY26 was ₹10.15 lakhs, compared to ₹7.90 lakhs in FY25.

• Total income for FY26 was ₹310.70 lakhs, up from ₹307.33 lakhs in FY25.

• Basic EPS for FY26 was ₹0.17, compared to ₹0.16 in FY25.

Outlook and guidance

• Management confirmed the company continues as a going concern and there are no indications of cessation of operations.